| Oct 9 |
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
|
| Sep 30 |
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
|
| Sep 26 |
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
|
| Sep 25 |
Windtree Therapeutics Heart Failure Drug Candidate Improves Systolic Blood Pressure
|
| Sep 25 |
Windtree stock slides amid Phase 2b data for istaroxime for cardiogenic shock
|
| Sep 25 |
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
|
| Sep 18 |
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket
|
| Sep 4 |
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock
|
| Aug 21 |
Windtree Therapeutics files to sell 27.67M shares of common stock for holders
|
| Aug 20 |
Windtree Therapeutics GAAP EPS of -$20.91 misses by $18.64
|
